Dr. Moises Roizental: All About Weight Management and Obesity Medication: GLP 1 Agonists

Know Your Physio

00:00 /

The ever-increasing issue of obesity and its related health complications brings with it the need for effective treatment. We are joined today by a board-certified vascular and interventional radiologist, Dr. Moises Roizental, to talk all things weight loss and obesity medication (specifically GLP-1 agonists). Dr. Roi explains the challenge of overcoming obesity and the role GLP-1 agonists play in alleviating the struggle. We learn about the multitude of benefits, obesity-related and otherwise, as well as the indications, contraindications, and side effects. Tune in to hear about the long-term benefits of investing in your health and how to get the best results from this life-changing medication!

Key Points From This Episode:

What “bioavailability” means. [00:22]
Introducing vascular and interventional radiologist, Dr. Moises Roizental. [03:13]
Introducing today’s topic: weight loss and obesity medication. [03:39]
Where to find the Spanish version of this episode. [04:23]
What GLP-1 agonists are, how they work, and their metabolic benefits. [05:59]
The weight loss results of GLP-1 agonists. [11:22]
What to pair the meds with to see results. [11:38]
Other non-obesity-related benefits of the medication. [12:09]
The history of the medication. [14:21]
Under which circumstances GLP-1 agonists are contraindicated. [15:15]
How GLP-1 agonists alleviate the challenge of overcoming obesity. [16:47]
Dr. Roi’s personal experimentation with the medication. [18:53]
The availability and accessibility of the meds. [20:39]
Some of the long-term benefits of investing in your health. [21:51]
The side effects of GLP-1 agonists. [23:49]
Controversial use/abuse of the medication. [24:54]
The recommended dosage of GLP-1 agonists. [27:29]
Dr. Roi’s advice for those interested in exploring this medication. [30:11]
Safe sources of GLP-1 agonists. [34:04]
Dr. Roi’s for the future of GLP-1 agonists. [35:45]
Why Dr. Roi has shifted from intervention towards disease prevention. [37:06]